The advent of biosimilars may render Etanercept (ETN) and Adalimumab (ADA) viable alternatives to methotrexate (MTX) as first line systemics in psoriasis. However, real-world relative effectiveness data comparing ADA and ETN to MTX are limited.
To estimate the relative effectiveness of ADA and ETN compared to MTX.
We analyzed data from DermaReg, a regional register in Stockholm, Sweden, to estimate drug survival and mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) during maintenance treatment.
524 patients initiated 727 treatment episodes with ADA, ETN, or MTX. After adjusting for confounders, patients treated with ADA had better drug survival (HR: 0.67; p=0.003), lower mean PASI (-2.0; p<0.001) and lower mean DLQI (-1.1; p<0.001) during maintenance treatment compared to patients treated with MTX. The results for ETN compared to MTX were mixed. After adjusting for confounding, there was no significant difference in drug survival (HR 1.23; p=0.082), but patients on ETN had lower mean PASI (- 0.7; p=0.007) during maintenance treatment.
Adalimumab is superior to MTX in clinical practice whereas the relative effectiveness between ETN and MTX is less clear. This study also highlights the importance of appropriate confounding control in effectiveness analysis.